Abelacimab

Source: Wikipedia, the free encyclopedia.

Abelacimab
Monoclonal antibody
TypeWhole antibody
TargetFactor XI and its active form Factor XIa
Clinical data
Other namesMAA868
AHFS/Drugs.comMonograph
License data
Intravenous
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
KEGG

Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.

Mechanism of action

It is anti-factor XI antibody.[1][2]

See also

References